InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (14 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
14
T+90 hit rate
100%
T+90 mean return
+17.9%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Albers Jeffrey W., Chairman & CEO. Director active across 3 companies, notably Blueprint Medicines Corp. In total, 54 filings have been published. Split: 0 buy · 14 sells. Total volume traded: €5.1m. Activity tracked since 12 May 2021. The latest transaction was filed on 13 October 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations54 total
5,000 shares@ US$10.346.2% of flowCommon StockSEC:0001193125-25-238130:0
5,000 shares@ US$59.189835.3% of flowCommon StockSEC:0001193125-25-238130:1
3,902 shares@ US$128.125.6% of flowCommon StockSEC:0001415889-25-018086:0
5,766 shares@ US$88.806.2% of flowCommon StockSEC:0001415889-25-008211:0
7,500 shares@ US$36.053.2% of flowCommon StockSEC:0001415889-25-008112:0
10,000 shares@ US$36.054.5% of flowCommon StockSEC:0001415889-25-001989:0
5,000 shares@ US$36.052.3% of flowCommon StockSEC:0001415889-25-001507:0
15,000 shares@ US$36.056.7% of flowCommon StockSEC:0001415889-24-029971:0
5,000 shares@ US$36.052.2% of flowCommon StockSEC:0001415889-24-026594:0
5,000 shares@ US$102.006.1% of flowCommon StockSEC:0001415889-24-026594:1
6,700 shares@ US$36.763195.7% of flowCommon StockSEC:0001636282-24-000089:0
300 shares@ US$36.434.3% of flowCommon StockSEC:0001636282-24-000070:0
10,000 shares@ US$36.054.2% of flowCommon StockSEC:0001415889-24-023204:0
5,000 shares@ US$10.346.4% of flowCommon StockSEC:0000950170-24-100660:0
2,242 shares0Common StockSEC:0001415889-24-016987:0
11,033 shares@ US$90.6911.8% of flowCommon StockSEC:0001415889-24-009169:0
15,073 shares@ US$1.870.3% of flowCommon StockSEC:0001415889-24-009009:0
615 shares@ US$10.340.8% of flowCommon StockSEC:0000950170-24-018246:0
15,000 shares@ US$1.870.3% of flowCommon StockSEC:0001415889-24-001931:0
10,000 shares@ US$10.3413.1% of flowCommon StockSEC:0000950170-24-006766:0
10,000 shares@ US$30.04738.1% of flowCommon StockSEC:0000950170-24-006766:1
5,000 shares@ US$36.052.2% of flowCommon StockSEC:0001415889-23-016360:0
34,360 shares0Common StockSEC:0000950170-23-069048:0
5,000 shares@ US$36.052.1% of flowCommon StockSEC:0001415889-23-015737:0
7,964 shares@ US$67.256.3% of flowCommon StockSEC:0001415889-23-015539:1
25 of 54 declarations
About Albers Jeffrey W.
Jeffrey W. Albers is the CEO and President at Blueprint Medicines Corp. He leads the company with a strategic vision focused on innovation in the biopharmaceutical sector. Albers is responsible for implementing growth and product development strategies. His leadership is essential for positioning Blueprint Medicines as a key player in the field of precision medicine.
